Ciclosporin ophthalmic - MC2 TherapeuticsAlternative Names: MC2-03; PADciclo 0.03%; PADciclo™; PAD™cyclosporine
Latest Information Update: 24 Jan 2017
At a glance
- Originator MC2 Biotek
- Developer MC2 Therapeutics; Moorfields Pharmaceuticals
- Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Dry eyes
Most Recent Events
- 01 Jul 2015 Phase-II clinical trials in Dry eyes (Combination therapy) in Austria and Denmark (Ophthalmic) (EudraCT2015-000937-54)